EUVIMEDEUVIMED entdecken
Open Access · CC0

Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver

Jeffrey Yang iD, Robert Morhard, Hannah Huth, Baktiar Karim, John W Karanian, Bradford J Wood, Andrew S Mikhail iD, Jenna L Mueller iD

PLOS One · 22.04.2026 · 21 (4) · e0347625

DOI: 10.1371/journal.pone.0347625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 22.04.2026. Verfasst von Jeffrey Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, United States of America. Hauptthemen laut MEDLINE: Ethanol, Colorectal Neoplasms, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: National Institutes of Health, National Cancer Institute, University of Maryland startup funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. A quarter of CRC patients develop liver metastases. Treatment options for liver metastases include surgically removing the tumors or undergoing liver transplantation; however, many patients are ineligible for these treatments due to severe extrahepatic disease or lack of suitable donors. Radiofrequency ablation offers an alternative local treatment modality for resolving CRC liver metastases and is known to generate antitumoral effects to stunt contralateral tumor growth. However, radiofrequency ablation is not suitable for tumors situated near critical structures or large blood vessels. Ethanol ablation is an alternative treatment option where pure ethanol is directly injected into tumors to induce necrosis and is unhindered by the drawbacks from radiofrequency ablation. The addition of ethyl cellulose with ethanol (EC-ethanol) enhances its retention within tissue and subsequently improves tumor ablative efficacy. However, the antitumoral response following EC-ethanol ablation in CRC tumors is poorly understood. Thus, we utilized a CRC murine model to investigate the immune effects following EC-ethanol treatment. Studies in the single flank model demonstrated up to a 27-fold increase in IL-6 and KC/GRO pro-inflammatory cytokines within 6 hours post-treatment compared to sham treatments, along with a 4-fold increase in target-tissue necrosis and increased cytotoxic T-cells within the vicinity of the ablation zone over 7 days. Studies in the bilateral flank tumor model demonstrated that EC-ethanol ablation on the primary tumor resulted in a 1.6-fold increase in cytotoxic T-cells within the contralateral tumor after 7 days compared to the sham control group. Combining EC-ethanol treatment with radiofrequency ablation resulted in a more pronounced, 2-fold increase in cytotoxic T-cells within the contralateral tumor. Altogether, these results suggest that EC-ethanol potentiates antitumoral effects in CRC tumors and is a strong therapeutic candidate for treating CRC patients worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EthanolColorectal NeoplasmsLiver NeoplasmsAnimalsMiceHumansGelsFemaleCell Line, Tumor

Substanzen

EthanolGels

Autor:innen und Institutionen

  • Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, United States of America.
  • Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Molecular Histopathology Laboratory, Laboratory Animal Science Program, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, Maryland, United States of America.
  • Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.

ORCID-Profile: Jeffrey Yang, Andrew S Mikhail, Jenna L Mueller

Förderung

  • National Institutes of Health
  • National Cancer Institute
  • University of Maryland startup funds
  • NCI/UMD Partnership for Integrative Cancer Research

Zitieren

APA

Yang, J., Morhard, R., Huth, H., Karim, B., Karanian, J. W., Wood, B. J., Mikhail, A. S., & Mueller, J. L. (2026). Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver. PLOS One, 21(4), e0347625. https://doi.org/10.1371/journal.pone.0347625

Vancouver

Yang J, Morhard R, Huth H, Karim B, Karanian JW, Wood BJ, et al. Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver. PLOS One. 2026;21(4):e0347625. doi:10.1371/journal.pone.0347625

BibTeX
@article{Yang2026,
  author = {Yang, Jeffrey and Morhard, Robert and Huth, Hannah and Karim, Baktiar and Karanian, John W and Wood, Bradford J and Mikhail, Andrew S and Mueller, Jenna L},
  title = {Antitumoral immunity induced by gel ethanol ablation to treat unresectable colorectal cancer metastases in the liver},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {4},
  pages = {e0347625},
  doi = {10.1371/journal.pone.0347625}
}
Kostenlos starten →